Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
10 June 2024 - 9:00PM
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage
biopharmaceutical company developing targeted protein modulation
drugs designed to treat patients with cancer and inflammatory
diseases, today announced that the company will host a webcast and
conference call at 9:00 a.m., ET, on Sunday, June 16, 2024, to
discuss data from the ongoing Phase 1 clinical trial of NX-5948
that will be presented in an oral session at the European
Hematology Association Congress in Madrid, Spain.
The oral presentation at EHA2024 will summarize updated data
from the ongoing Phase 1a/b study of NX-5948 in heavily pretreated
patients with relapsed/refractory chronic lymphocytic leukemia
(CLL) and non-Hodgkin lymphoma, including patients with BTK
inhibitor resistance mutations and CNS involvement.
Details of the webcast and conference call are as follows:
Date and time: Sunday, June 16, 9:00 a.m. ET /
3:00 p.m. CEST
Access details: The live webcast will be
accessible on the Events and Presentations page in the Investors
section of the company’s website here. To participate in the live
conference call, please pre-register online here. A replay of the
webcast and call will be archived on the Nurix website for
approximately 30 days after the event.
Details of the oral presentation at EHA2024 are as follows:
Title: Latest results from an ongoing
first-in-human Phase 1a/b study of NX-5948, a selective Bruton’s
tyrosine kinase (BTK) degrader, in patients with
relapsed/refractory CLL and other B-cell
malignancies.Session: s445 Novel therapies in
relapsed and refractory CLL and hairy cell leukemiaSession
Date and Time: Sunday, June 16, 11:30 a.m. – 12:45 p.m.
CESTLocation: Hall
VelasquezPresenter: Dr. Kim LintonAbstract
#: S155
About NX-5948
NX-5948 is an investigational, orally bioavailable, brain
penetrant, small molecule degrader of BTK. NX-5948 is currently
being evaluated in a Phase 1 clinical trial in patients with
relapsed or refractory B cell malignancies. Nurix has previously
reported that NX-5948 is highly potent against a range of tumor
cell lines that are resistant to current BTK inhibitor therapies,
an important consideration in heavily pretreated CLL/SLL patient
populations. Additional information on the ongoing clinical trial
can be accessed at clinicaltrials.gov (NCT05131022).
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
innovative small molecules and antibody therapies based on the
modulation of cellular protein levels as a novel treatment approach
for cancer, inflammatory conditions, and other challenging
diseases. Leveraging extensive expertise in E3 ligases together
with proprietary DNA-encoded libraries, Nurix has built DELigase,
an integrated discovery platform, to identify and advance novel
drug candidates targeting E3 ligases, a broad class of enzymes that
can modulate proteins within the cell. Nurix’s drug discovery
approach is to either harness or inhibit the natural function of E3
ligases within the ubiquitin-proteasome system to selectively
decrease or increase cellular protein levels. Nurix’s wholly owned,
clinical stage pipeline includes targeted protein degraders of
Bruton’s tyrosine kinase, a B-cell signaling protein, and
inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3
ligase that regulates activation of multiple immune cell types
including T cell and NK cells. Nurix is headquartered in San
Francisco, California. For additional information
visit http://www.nurixtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and other federal securities laws. Any statements contained
herein that do not describe historical facts, including, but not
limited to, statements regarding Nurix’s intention to present and
discuss updated NX-5948 clinical trial data at and in connection
with EHA2024, are forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially
from those discussed in such forward-looking statements. Such risks
and uncertainties include, among others, the risks described under
the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q
for the period ended February 29, 2024, and subsequent filings with
the SEC. Any of these risks and uncertainties could materially and
adversely affect Nurix’s business and results of operations, which
could, in turn, have a significant and adverse impact on Nurix’s
stock price. Nurix cautions you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. Nurix undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date they were made or to reflect the
occurrence of unanticipated events.
Contacts:
Investors
Jason Kantor, Ph.D.Nurix Therapeuticsir@nurixtx.com
Elizabeth Wolffe, Ph.D.Wheelhouse Life Science
Advisorslwolffe@wheelhouselsa.com
Media
Aljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Sep 2023 to Sep 2024